Processing

Please wait...

Settings

Settings

Goto Application

1. WO2008060331 - ANTIBODIES TO SARS CORONAVIRUS

Publication Number WO/2008/060331
Publication Date 22.05.2008
International Application No. PCT/US2007/012136
International Filing Date 21.05.2007
IPC
C07K 16/10 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
CPC
A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses ; , e.g. hepatitis E virus
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
C07K 2317/56
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
56variable (Fv) region, i.e. VH and/or VL
Applicants
  • AMGEN INC. [US]/[US] (AllExceptUS)
  • BABCOOK, John, S. [CA]/[CA] (UsOnly)
  • PRABHAKAR, Bellur, S. [US]/[US] (UsOnly)
  • COUGHLIN, Melissa [US]/[US] (UsOnly)
Inventors
  • BABCOOK, John, S.
  • PRABHAKAR, Bellur, S.
  • COUGHLIN, Melissa
Agents
  • GUNNISON, Jane, T.
Priority Data
60/801,95119.05.2006US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTIBODIES TO SARS CORONAVIRUS
(FR) ANTICORPS AU CORONAVIRUS SRAS
Abstract
(EN)
The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to human severe acute respiratory syndrome coronavirus (SARS-CoV S) protein, and that function to neutralize SARS-CoV. The invention also relates to antibodies that are bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and 'light chain immunoglobulins derived from human anti- SARS-CoV S protein antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also, provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-SARS-CoV S protein antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of. the present invention.
(FR)
La présente invention concerne des anticorps qui comprennent des anticorps humains et des parties de liaison à un antigène de ceux-ci se liant spécifiquement à la protéine de SRAG-CoV humaine, et fonctionnant pour neutraliser le SRAG-CoV. La présente invention concerne également des anticorps qui sont des anticorps monocaténaires bispécifiques dérivés, ou des parties de protéine de fusion. L'invention concerne également des immunoglobulines à chaînes lourdes et légères dérivées d'anticorps de protéine anti-SRAG-CoV S humaine et des molécules d'acide nucléique encodant de telles immunoglobulines. La présente invention concerne également des procédés d'utilisation des anticorps et des compositions pour le diagnostic et le traitement. L'invention fournit également des procédés de thérapie génique utilisant des molécules d'acide nucléique encodant les molécules d'immunoglobuline lourdes et/ou légères qui comportent les anticorps de protéine anti-SRAG-CoV S humaine. L'invention concerne également des animaux ou des végétaux transgéniques comportant les molécules d'acide nucléique de la présente invention.
Latest bibliographic data on file with the International Bureau